StockData
Sigyn Therapeutics, Inc. logo

Sigyn Therapeutics, Inc. (SIGY) stock

SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 0/30
$0.03+0.00 (0.00%)

Close on Oct 19, 2026Market cap $48.16KP/E –Yield –

Sigyn Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Sigyn Therapeutics's operating income for the twelve months ending Sep 30, 2025 was -$1.88M. For fiscal 2024 it was -$2.52M. The highest annual figure on record is -$387.54K in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$2.52M–
FY2023Dec 31, 2023-$2.46M–
FY2022Dec 31, 2022-$2.15M–
FY2021Dec 31, 2021-$2.01M–
FY2020Dec 31, 2020-$916.43K–
FY2019Dec 31, 2019-$517.96K–
FY2018Dec 31, 2018-$1.00M–
FY2017Dec 31, 2017-$2.03M–
FY2015Dec 31, 2015-$2.25M–
FY2014Dec 31, 2014-$387.54K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2025Sep 30, 2025-$386.53K–
Q2 FY2025Jun 30, 2025-$469.51K–
Q1 FY2025Mar 31, 2025-$546.06K–
Q4 FY2024Dec 31, 2024-$478.01K–
Q3 FY2024Sep 30, 2024-$808.46K–
Q2 FY2024Jun 30, 2024-$602.81K–
Q1 FY2024Mar 31, 2024-$629.97K–
Q4 FY2023Dec 31, 2023-$717.24K–
Q3 FY2023Sep 30, 2023-$642.81K–
Q2 FY2023Jun 30, 2023-$574.01K–
Q1 FY2023Mar 31, 2023-$521.26K–
Q4 FY2022Dec 31, 2022-$471.59K–
Q3 FY2022Sep 30, 2022-$533.65K–
Q2 FY2022Jun 30, 2022-$532.80K–
Q1 FY2022Mar 31, 2022-$609.24K–
Q4 FY2021Dec 31, 2021-$590.94K–
Q3 FY2021Sep 30, 2021-$573.36K–
Q2 FY2021Jun 30, 2021-$441.82K–
Q1 FY2021Mar 31, 2021-$402.10K–
Q4 FY2020Dec 31, 2020-$344.57K–
Q3 FY2020Sep 30, 2020-$202.98K–
Q2 FY2020Jun 30, 2020-$175.91K–
Q1 FY2020Mar 31, 2020-$192.98K–
Q4 FY2019Dec 31, 2019-$125.06K–
Q3 FY2019Sep 30, 2019-$122.73K–
Q2 FY2019Jun 30, 2019-$101.32K–
Q1 FY2019Mar 31, 2019-$168.86K–
Q4 FY2018Dec 31, 2018-$241.48K–
Q3 FY2018Sep 30, 2018-$241.30K–
Q2 FY2018Jun 30, 2018-$233.09K–
Q1 FY2018Mar 31, 2018-$288.24K–
Q4 FY2017Dec 31, 2017-$491.67K–
Q3 FY2017Sep 30, 2017-$580.21K–
Q2 FY2017Jun 30, 2017-$615.33K–
Q1 FY2017Mar 31, 2017-$344.17K–
Q3 FY2016Sep 30, 2016-$329.44K–
Q2 FY2016Jun 30, 2016-$526.88K–
Q1 FY2016Mar 31, 2016-$712.68K–
Q4 FY2015Dec 31, 2015-$811.96K–

More Sigyn Therapeutics figures

See a number that looks wrong?